Key Bristol Myers drug holds up in long-term psoriasis study
Bio Pharma Dive
MAY 12, 2022
Deucravacitnib, forecast by Bristol Myers to hit $4 billion in peak sales, is under FDA review with an approval decision due by September. The agency's view of its safety will be key to its future.
Let's personalize your content